Last reviewed · How we verify

NCT03725566

JY028 Single Vitreous Injection in a Phase 1 Clinical Trial in nAMD Patients

Status unknown NA Last updated 31 October 2018
What this trial tests

NA trial testing Experimental in Macular Degeneration in 24 participants. Status unknown.

Timeline
22 May 2018
Primary endpoint
1 May 2020
1 May 2020

Quick facts

Lead sponsorBeijing Tongren Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Designsequential
Maskingnone
Primary purposeother
Enrollment24
Start date22 May 2018
Primary completion1 May 2020
Estimated completion1 May 2020
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Tongren Hospital

Who can join

Adults 50 to 75, any sex, with Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase I clinical trial on safety, tolerance, pharmacokinetics (PK) and pharmacodynamics of recombinant human anti-VEGF monoclonal antibody injection in patients with neovascular (wet) age-related macular degeneration

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Experimental

Trials testing the same drug.

Other recruiting trials for Macular Degeneration

Currently open trials in the same condition.

Other Beijing Tongren Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03725566.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing